ISTANBUL: Vaccines have been developed by several countries to prevent the spread of the corona virus, which is being used globally to vaccinate the public.
In this regard, the Covid 19 vaccine developed by the Chinese company Sinowek is up to 83.5% effective in protecting against the disease. This was revealed in the provisional results of the third phase trial of this vaccine in Turkey.
The results, published in the medical journal The Lancet, show that the vaccine provides 100 percent protection against the risk of hospitalization if infected with Covid 19. Synovik’s Corona Week vaccine is based on a dysfunctional Corona virus that cannot replicate itself.
However, the immune system can be trained to make antibodies based on this dysfunctional virus, meaning that if an individual is exposed to the virus after vaccination, his or her body may be better able to resist the disease or reduce its severity.
Corona Week has been approved for emergency use in 37 countries, including Pakistan, and the World Health Organization (WHO) approved it on June 1, 2021, but Corona Week’s trials are still ongoing.
The latest results came from a third round of vaccine trials in Turkey, a controlled double-blind randomized trial involving 10,029 people. These individuals were either given 2 doses of the vaccine at 14-day intervals or were given a placebo.
The volunteers in the trial ranged in age from 18 to 59, and did not include people who had previously been infected with covidosis or were undergoing immunosuppressive treatment.
Similarly, pregnant or breastfeeding women, people allergic to the vaccine, or people with autoimmune diseases were not included in the trial.
The researchers tested the PCR at least 14 days after the second dose of the vaccine to confirm the prevention of covid in volunteers.
They were then tested for 43 days and the researchers wanted to extend the period, but it was stopped after the vaccine was approved for emergency use in Turkey.
After analyzing all the data, the researchers found that Corona Vic is up to 83.5% effective in protecting against symptomatic disease.
Nine of the 6,559 people in the vaccine group were diagnosed with symptomatic disease 14 days after using the second dose. In contrast, 32 of the 3,470 members of the placebo group became ill.
According to the data, the vaccine provided 100% protection against covid admissions, but the researchers said that in the trial, only 6 people from the placebo group were admitted to the hospital due to cod, while no one from the vaccine group had to be admitted.
Corona Week also proved to be the safest vaccine in the trial, with only 19% of people in the vaccine group reporting side effects.
More than 90% of them had mild side effects and more than 50% did not experience them for more than a day. The researchers said that the world needs every dose of any safe and effective vaccine against cobwebs.
“Our findings show that Corona Week is very effective in preventing symptomatic disease and hospitalization, while also being safe for the population between the ages of 18 and 59,” he said.
However, the trial is limited in some respects, and according to the researchers, the analysis included young and low-risk populations, while the follow-up period was very short.
He said more data was needed to determine the safety and effectiveness of the vaccine, while examining its safety and efficacy in the elderly, children, adolescents and people with chronic diseases.
He said there was also a need to test its effectiveness against new strains of the corona virus.